论文部分内容阅读
目的 :比较不同剂量碘化钾缓释片和胶囊的驱铅作用。方法 :分成 4组。A组口服碘化钾胶囊 1g·d- 1,B组口服碘化钾缓释片 1g·d- 1,C组口服碘化钾胶囊 0 .5 g·d- 1,D组口服碘化钾缓释片 ,0 .5 g·d- 1,疗程 4wk。观察尿铅排泄 ,并比较用药前后血铅、血锌卟啉 (ZPP)、δ 氨基脱水酶 (δ ALA)及甲状腺素 (T3,T4 )浓度。结果 :4组均有不同程度增加尿铅排泄 ,降低血铅、尿ZPP和δ ALA作用。T3,T4 治疗前后差异有显著意义。口服碘化钾 1g胶囊制剂不良反应最大 ,主要表现为乏力、上腹隐痛 ,分别为 3 1%和 45 % ;口服缓释片 0 .5 g·d- 1,不良反应最小 ,5 %有乏力和口干口苦。结论 :碘化钾具有驱铅作用 ,推荐成人剂量为 0 .5 g·d- 1,且以缓释片为宜。
OBJECTIVE: To compare the lead-removing effects of different doses of potassium iodide sustained-release tablets and capsules. Methods: Divided into 4 groups. A group of oral potassium iodide capsules 1g · d-1, B group oral potassium iodine sustained release tablets 1g · d-1, C group orally administered potassium iodide capsules 0.5 g · d-1, D group oral potassium iodide sustained release tablets, 0.5 g D-1, treatment 4wk. The urinary excretion of urine was observed. The levels of blood lead, ZPP, δ ALA and T3, T4 were compared before and after treatment. Results: All the four groups had different degrees of excretion of urinary lead and decreased the effects of blood lead, urine ZPP and δ ALA. T3, T4 before and after treatment were significant differences. Oral administration of potassium iodide 1g capsules showed the largest adverse reactions, mainly manifested as fatigue, upper abdominal pain, respectively, 3 1% and 45%; Oral sustained-release tablets 0.5 g · d-1, minimal adverse reactions, 5% Dry mouth bitter. Conclusion: Potassium iodide has the effect of expelling lead, and the recommended adult dosage is 0.5 g · d-1.